Last reviewed · How we verify
NCT06569472
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Phase 1 trial testing CD19-targetd CAR-T in Juvenile Dermatomyositis in 10 participants. Currently enrolling.
31 July 2027
Quick facts
| Lead sponsor | Chongqing Precision Biotech Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 2 July 2024 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 July 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19-targetd CAR-T — full drug profile →
Conditions studied
- Juvenile Dermatomyositis — all drugs for Juvenile Dermatomyositis →
Sponsor
Chongqing Precision Biotech Co., Ltd — full company profile →
Who can join
Adults 5 to 17, any sex, with Juvenile Dermatomyositis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases.
Jiang M, Zhao J, Yuan J, Yu Z, et al · · 2025 · cited 2× · PMID 40747591 · DOI 10.1080/21645515.2025.2538350 -
The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care.
Ciurtin C, Sparchez M, Elephtheriou D, Brogan P. · · 2025 · PMID 40845184 · DOI 10.1093/rheumatology/keaf455
Verify or expand the search:
- PubMed search for NCT06569472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Juvenile Dermatomyositis
Currently open trials in the same condition.
- NCT01276470 — Environmental Risk Factors for the Anti-synthetase Syndrome · recruiting
- NCT00059748 — Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositi · recruiting
Other Chongqing Precision Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07184450 — Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases · Phase 1 · recruiting
- NCT07239323 — In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies · Phase 1 · recruiting
- NCT06892145 — Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06569472 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Precision Biotech Co., Ltd
- Last refreshed: 26 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06569472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing